Daniel E Johnson
Overview
Explore the profile of Daniel E Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
9734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen J, Naara S, Woerner L, VanLandingham N, Hoerner M, Santuray R, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39976130
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of PTEN (phosphatase and tensin homolog deleted on chromosome 10) is one of the most common...
2.
Fu B, Xu A, Li H, Johnson D, Grandis J, Gilbert L
bioRxiv
. 2025 Feb;
PMID: 39896609
Mutations in the FA pathway lead to a rare genetic disease that increases risk of bone marrow failure, acute myeloid leukemia, and solid tumors. FA patients have a 500 to...
3.
Underrepresentation of Hispanic women in science, technology, engineering, mathematics, and medicine
Gencel-Augusto J, Minaya N, Johnson D, Grandis J
CA Cancer J Clin
. 2025 Jan;
PMID: 39785094
Despite ongoing efforts to increase the number of women in science, technology, engineering, and mathematics (STEM) and in medicine, Hispanic women remain severely underrepresented in these fields. This disparity not...
4.
Callander J, Johnson D, Grandis J
Cancer
. 2024 Nov;
131(1):e35667.
PMID: 39612169
Gender disparities in academic medicine persist despite gender parity among medical school graduates. Women remain underrepresented in higher academic ranks and leadership roles, with significant differences in retention, promotion, and...
5.
Nguyen J, Woerner L, Johnson D, Grandis J
Expert Rev Anticancer Ther
. 2024 Oct;
24(11):1067-1084.
PMID: 39412140
Areas Covered: Here we describe novel agents, their mechanism(s) of action, preclinical results, and ongoing clinical trials in HNSCC. Expert Opinion: Established therapeutic targets in HNSCC include EGFR (cetuximab) and...
6.
Cui Z, Kang H, Li H, Lee E, Lee Y, Peterson C, et al.
Head Neck
. 2024 Sep;
47(2):606-614.
PMID: 39347568
Background: Human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is an emerging epidemic and a subset of HPV-positive patients experience aggressive disease with metastases. The CYLD gene...
7.
Chung D, Kong S, Young N, Chuo S, Shiah J, Connelly E, et al.
Commun Biol
. 2023 Oct;
6(1):1036.
PMID: 37828150
In vitro biopanning platforms using synthetic phage display antibody libraries have enabled the identification of antibodies against antigens that were once thought to be beyond the scope of immunization. Applying...
8.
Lee R, Johnson D, Grandis J
Cancer Res
. 2023 Oct;
83(19):3162-3164.
PMID: 37779427
Meaningful advances in targeted therapy for head and neck squamous cell carcinoma (HNSCC) have been hampered by limited availability of robust preclinical models for translational research. Using an impressive array...
9.
Lee R, Roy R, Li H, Hechmer A, Zhu T, Izgutdina A, et al.
PLoS One
. 2023 Mar;
18(3):e0282177.
PMID: 36857322
There are currently no clinical strategies utilizing tumor gene expression to inform therapeutic selection for patients with head and neck squamous cell carcinoma (HNSCC). One of the challenges in developing...
10.
Shiah J, Johnson D, Grandis J
Cancer J
. 2023 Jan;
29(1):38-46.
PMID: 36693157
Cancer is defined by the presence of uncontrollable cell growth, whereby improper proliferative signaling has overcome regulation by cellular mechanisms. Transcription factors are uniquely situated at the helm of signaling,...